Pazopanib bulk supplier for pharma manufacturers

Pazopanib 200mg, 400mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 200mg, 400mg

Reference Brands: Votrient

Pazopanib is a tyrosine kinase inhibitor (TKI) used in the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma. It works by inhibiting multiple tyrosine kinases involved in tumor growth and angiogenesis (the formation of new blood vessels), thereby slowing or stopping the progression of cancer.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Pazopanib? List it or send an offer →

Product Description:

Pazopanib inhibits VEGF receptors one to three, PDGFR-alpha and beta, and KIT, cutting off the blood supply a solid tumour needs to grow beyond a few millimetres. Its position among the antiangiogenic kinase inhibitors rests less on superior potency than on tolerability: in a direct comparison in kidney cancer against sunitinib it showed similar efficacy with a different and, to most patients, preferable side effect profile, particularly less fatigue and hand-foot syndrome.

It is used for advanced renal cell carcinoma and for advanced soft tissue sarcoma after prior chemotherapy, taken once daily on an empty stomach — food substantially increases absorption and risks overdose. Hepatotoxicity is the defining safety issue and carries a boxed warning, with liver function monitored before treatment and repeatedly during the first months. Hypertension, diarrhoea, hair colour change, QT prolongation, haemorrhage and impaired wound healing occur; treatment is stopped before surgery.

Sourcing notes. Originator in most markets, with generic entry in some — confirm per destination. Two tablet strengths support dose reduction, which is frequent. Liver function monitoring capability at the destination is a practical prerequisite. Oral solid, room temperature.

Pazopanib — third party manufacturing & bulk supply

Pazopanib 200mg, 400mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Pazopanib is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Pazopanib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Pazopanib →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Pazopanib is listed as Tablets in 200mg, 400mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Pazopanib is referenced against Votrient. Reference brands are shown for identification only and remain the property of their respective trademark owners.